CN113056276A - 用于产生组织驻留记忆样t细胞的方法及其用途 - Google Patents

用于产生组织驻留记忆样t细胞的方法及其用途 Download PDF

Info

Publication number
CN113056276A
CN113056276A CN201980076103.7A CN201980076103A CN113056276A CN 113056276 A CN113056276 A CN 113056276A CN 201980076103 A CN201980076103 A CN 201980076103A CN 113056276 A CN113056276 A CN 113056276A
Authority
CN
China
Prior art keywords
cells
cell
antigen
express
itgae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980076103.7A
Other languages
English (en)
Chinese (zh)
Inventor
C·翊
F·哈森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN113056276A publication Critical patent/CN113056276A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201980076103.7A 2018-10-18 2019-10-18 用于产生组织驻留记忆样t细胞的方法及其用途 Pending CN113056276A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862747523P 2018-10-18 2018-10-18
US62/747,523 2018-10-18
US201962846270P 2019-05-10 2019-05-10
US62/846,270 2019-05-10
PCT/US2019/057016 WO2020081987A1 (en) 2018-10-18 2019-10-18 Methods for production of tissue resident memory-like t cells and use thereof

Publications (1)

Publication Number Publication Date
CN113056276A true CN113056276A (zh) 2021-06-29

Family

ID=70284129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980076103.7A Pending CN113056276A (zh) 2018-10-18 2019-10-18 用于产生组织驻留记忆样t细胞的方法及其用途

Country Status (7)

Country Link
US (2) US12319740B2 (https=)
EP (1) EP3866814A4 (https=)
JP (2) JP7698577B2 (https=)
KR (1) KR20210078518A (https=)
CN (1) CN113056276A (https=)
CA (1) CA3115487A1 (https=)
WO (1) WO2020081987A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115975921A (zh) * 2022-12-09 2023-04-18 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种体外诱导组织驻留性记忆cd8+t细胞的方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
GB202007321D0 (en) * 2020-05-18 2020-07-01 Inst De Medicina Molecular Joaeo Lobo Antunes T cells
CN111944749A (zh) * 2020-08-14 2020-11-17 福建医科大学附属协和医院 一种用于治疗心肌梗死的人脂肪间充质干细胞外泌体的制备方法
CN112516141A (zh) * 2020-12-07 2021-03-19 浙江大学 Cd47表达抑制剂及其与免疫治疗药物联合使用
US20240368545A1 (en) * 2021-05-07 2024-11-07 Yasuhito TOKUMOTO Manufacturing method of memory t cells
US20250281539A1 (en) * 2022-05-10 2025-09-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of culturing tumor infiltrating lymphocytes
WO2024253594A1 (en) * 2023-06-07 2024-12-12 Agency For Science, Technology And Research Small molecule based method of modifying t cells
WO2025076124A1 (en) * 2023-10-02 2025-04-10 Immunitybio, Inc. Methods of generating, stimulating, or increasing proliferation of different subsets of cd8+ t cells
WO2025096644A1 (en) * 2023-10-31 2025-05-08 Immunitybio, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of advanced solid tumors
WO2025129119A1 (en) * 2023-12-15 2025-06-19 La Jolla Institute For Immunology Gpr25 agonization for cancer therapy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
US20080131415A1 (en) * 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
US20150299656A1 (en) * 2012-09-06 2015-10-22 The United States of America, as represented by th Secretary, Department of Health and Human Service Methods of producing t memory stem cell populations
WO2017079113A1 (en) * 2015-11-02 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Healh And Human Services Methods of producing t cell populations using prolyl hydroxylase domain-containing protein inhibitors
US20180117021A1 (en) * 2015-03-27 2018-05-03 Shenyang Sunshine Pharmaceutical Co. Ltd. Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof
WO2018106972A1 (en) * 2016-12-07 2018-06-14 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017015024A1 (en) 2015-07-20 2017-01-26 Mayo Foundation For Medical Education And Research Methods and materials for producing t cells
US20240197782A1 (en) * 2021-04-20 2024-06-20 Board Of Regents, The University Of Texas System Methods and compositions for genetic modification and therapeutic use of immune cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
US20080131415A1 (en) * 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
US20150299656A1 (en) * 2012-09-06 2015-10-22 The United States of America, as represented by th Secretary, Department of Health and Human Service Methods of producing t memory stem cell populations
US20180117021A1 (en) * 2015-03-27 2018-05-03 Shenyang Sunshine Pharmaceutical Co. Ltd. Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof
WO2017079113A1 (en) * 2015-11-02 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Healh And Human Services Methods of producing t cell populations using prolyl hydroxylase domain-containing protein inhibitors
WO2018106972A1 (en) * 2016-12-07 2018-06-14 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAMUEL KOPRAK ET AL.: "Down-regulation of cell surface CXCR6 expression during T cell activation is predominantly mediated by calcineurin", 《CELLULAR IMMUNOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115975921A (zh) * 2022-12-09 2023-04-18 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种体外诱导组织驻留性记忆cd8+t细胞的方法

Also Published As

Publication number Publication date
JP7698577B2 (ja) 2025-06-25
KR20210078518A (ko) 2021-06-28
CA3115487A1 (en) 2020-04-23
EP3866814A4 (en) 2022-07-27
US20250320306A1 (en) 2025-10-16
US12319740B2 (en) 2025-06-03
EP3866814A1 (en) 2021-08-25
US20210355443A1 (en) 2021-11-18
WO2020081987A1 (en) 2020-04-23
JP2025084776A (ja) 2025-06-03
JP2022505194A (ja) 2022-01-14

Similar Documents

Publication Publication Date Title
US20250320306A1 (en) Methods for production of tissue resident memory-like t cells and use thereof
KR102865130B1 (ko) 향상된 키메라 항원 수용체 및 그의 용도
EP3212225B1 (en) Methods and compositions for modified t cells
CN117305250A (zh) 工程化天然杀伤细胞及其用途
JP7447011B2 (ja) エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用
BR112019005633A2 (pt) tcrs específicos para antigênio ha-1 de histocompatibilidade (h) menor e usos dos mesmos
CA3114788A1 (en) Immunoresponsive cells expressing dominant negative fas and uses thereof
CN117802051A (zh) 修饰的细胞及组合物
CN112292140B (zh) 靶向cd37和cd19的嵌合抗原受体
JP2021512637A (ja) サイクリンａ１特異的ｔ細胞受容体およびその使用
JP2025085740A (ja) シアリルルイスａを標的とするキメラ抗原受容体およびその使用
JP2021534752A (ja) Ｋｒａｓ抗原またはｈｅｒ２抗原を標的とする免疫療法
WO2023164475A1 (en) Modified invariant natural killer t cells expressing a chimeric antigen receptor and uses thereof
JP2024514149A (ja) ｕＰＡＲを標的とするＣＡＲ－Ｔ細胞及びその使用
JP2025515324A (ja) がんを処置するためのキメラ抗原受容体改変調節性ｔ細胞
JP2024534767A (ja) キメラ抗原受容体がん免疫療法の有効性を増強するためのＢｃｌ－２の調節
US12552851B2 (en) T cell receptors with VGLL1 specificity and uses thereof
US11883430B2 (en) CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy
WO2025029648A1 (en) Compositions and methods for targeting loxhd1-associated disease
Succi High-throughput CRISPR-Cas9 screening in CAR-T cells as a platform for the identification of novel immunomodulatory targets
Kerr Modulation of T Cells to Promote an Anti-Tumor Response: Activation And Inhibition Of T Cells For Efficacy In T-Cell Lymphomas And Melanoma
CN119894923A (zh) 包含tmigd2共刺激结构域的嵌合抗原受体及其相关使用方法
WO2026085184A1 (en) Cd2 chimeric switch receptors and uses thereof for adoptive cell transfer immunotherapy
CN115052973A (zh) 用于产生细胞毒性效应子记忆t细胞以用于癌症的t细胞治疗的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination